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August 9, 2011:775–8risk of mortality or major morbidity and a group of 7 individual
risk factors that had been shown to account for the bulk of the
outcomes observed. It is undoubtedly true that other risk factors
exist; however, the benefit of adding covariates in a statistical
model must be weighed against the risk of overfitting and
detecting spurious associations (4). In light of this, we, like many
others, opted for a parsimonious model containing core risk factors
rather than exhaustive ones.
Good clinical practice dictates that the incorporation of new
tests and treatments should be based on sound evidence, ideally
from more than a single study. As stated in our paper, we
wholeheartedly endorse and look forward to future efforts to study
the optimal cutoff for slow gait speed and to validate the role of gait
speed as a prognostic marker in patients undergoing cardiac
surgery.
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Valve Academic Research
Consortium Consensus Report
The Pharmaceutical and
Medical Devices Agency Perspective
First, we sincerely express our appreciation for the organized effort
by the Valve Academic Research Consortium (VARC) members(1). Similar to the United States, there is no approved transcatheter
aortic valve implantation (TAVI) device in Japan at present. We
believe that this VARC consensus report is beneficial, even for the
Pharmaceutical and Medical Devices Agency (PMDA), which is
the regulatory authority in Japan.
Although we believe that the consensus is already well orga-
nized, we comment here on several points from the PMDA
perspective.
1. The definition of intended performance of the prosthetic heart
valve. Considering implantation in smaller body size, such as in
Asian patients, or future possible expansion of the size variation of
TAVI device, the critical value of 1.2 cm2 for the aortic valve area
ay need some adjustment based on patient body size or device
ize.
. Hospitalization criteria variance among countries. We bring to
our attention that there will be a possible bias by each country’s
edical care setting. For example, the threshold of hospitalization
ould be lower in Japan than in United States or the European
nion.
. Evaluation of stroke. The consensus proposed the modified
ankin Scale (mRS) score at 30 and 90 days for the stroke
efinition. We suggest that National Institutes of Health Stroke
cale (NIHSS) should also be used, and the time point of the
valuations should cover event onset (acute phase) as well, first,
ecause generally the mRS score would be appropriate for the
elatively chronic phase and NIHSS would be more appropriate for
he acute phase and, second, because immediate treatment of
troke will greatly influence the mRS score at 30 and 90 days, and
ts evaluation would not properly reflect the impact as a TAVI
omplication. In addition, the NIHSS was proposed in U.S. Food
nd Drug Administration guidelines (2) in 2007 for a neurothrom-
ectomy device and used in many clinical studies for cerebrovas-
ular disorders.
We hope that our comments contribute to honing the criteria
onsensus further.
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